Eupraxia Pharmaceuticals Inc. EPRX
Free
No email, no account, no signup.
General analysis — not personal advice.
Bull
Bear
Want to follow Eupraxia Pharmaceuticals Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Exchange
NASDAQ
Type
Biotech
Sector
Clinical biotechnology and drug development
Price & valuation
Last close
USD 6.70
1 week
+3.4 %
3 months
-11.3 %
12 months
+24.7 %
From 52w high
-26.1 %
From 52w low
+32.7 %
We're already tracking Eupraxia Pharmaceuticals Inc. — here are the latest events we've registered
Recent News
- On July 13, 2026, Eupraxia Pharmaceuticals announced executive leadership additions and operational relocation as it prepares for late-stage clinical development. Dr. Jeff Millard joined as Executive Vice President of Technical Operations, while Dr. Alex Therien assumed leadership of Research and Development. The updates support preparations for Phase 3 trials and commercial scale-up for its lead candidate, EP-104GI.
What Firelda Watch includes for Eupraxia Pharmaceuticals Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Eupraxia Pharmaceuticals Inc. will be delivered in the same format.
Want to follow Eupraxia Pharmaceuticals Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.